Life Course Malaria Exposure and SARS ‐ CoV ‐2 Seroepidemiology in Ugandan Adolescents: A Longitudinal Study Nested in a Birth Cohort
Tropical Medicine & International Health · 2026-08 · 31 (8) · 1012-1027
DOI: 10.1111/tmi.70148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tropical Medicine & International Health, online erschienen am 23.04.2026. Verfasst von Ludoviko Zirimenya und 22 weiteren Autor:innen. Beteiligte Einrichtung: Immunomodulation and Vaccines Focus Area, Vaccine Research Theme, Medical Research Council/Uganda Virus Research Institute and London School of Hygie…. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Malaria. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science for Africa Foundation, National Institute for Health and Care Research, LSHTM ITD Faculty Equity.
Abstract (Originalsprache)
Background
COVID‐19 has had major global health impacts, yet reported morbidity and mortality have been lower in Africa despite serological evidence of widespread infection. Malaria has been proposed as a potential modifier of susceptibility to and outcomes of SARS‐CoV‐2 infection. We investigated whether prospectively measured life‐course malaria exposure was associated with serologically defined SARS‐CoV‐2 infection among adolescents in a malaria‐endemic setting and explored symptomatic COVID‐19 during follow‐up.
Methods
We conducted a longitudinal study nested within the Entebbe Mother and Baby Study birth cohort in Uganda. Adolescents were enrolled and followed up 6 and 12 months later. Blood samples were collected at each visit for SARS‐CoV‐2 serology. Malaria exposure was defined using prospectively collected data on clinical malaria (from birth to 10 years), asymptomatic parasitaemia at annual visits and antibody responses to Plasmodium falciparum merozoite surface protein 2 (PfMSP‐2) and apical membrane antigen 1 (PfAMA‐1). The primary outcome was SARS‐CoV‐2 seropositivity, based on spike and nucleocapsid IgG responses, with seropositivity cut‐offs derived from pre‐pandemic samples. Secondary outcomes, including antibody concentrations and symptomatic PCR‐confirmed disease, were explored. Vaccinated participants were excluded from subsequent serological analyses. Logistic and linear regression models assessed associations with seropositivity and log 10 ‐transformed antibody concentrations, adjusting for key demographic, socioeconomic and exposure‐related confounders.
Results
Between August and November 2021, 476 adolescents (mean age 16.4 years (SD = 0.75); 205 (43.1%) female) were enrolled. Overall, 12.0% had ever had asymptomatic parasitaemia, and 61.3% had experienced clinical malaria. SARS‐CoV‐2 seropositivity among unvaccinated participants increased from 63% at baseline to 89.3% at 6 months and 94.9% at 12 months; no PCR‐positive cases were reported. Multivariable analyses showed no consistent association between malaria exposure and SARS‐CoV‐2 seropositivity or antibody concentration levels.
Conclusions
We found no consistent evidence that life‐course malaria exposure was associated with SARS‐CoV‐2 infection as measured by serology or antibody levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Immunomodulation and Vaccines Focus Area, Vaccine Research Theme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI and LSHTM) Uganda Research Unit, En…
- Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.
- Department of Infectious Diseases, King's College London, London, UK.
- Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK.
- Viral Pathogen Theme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
- Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda.
ORCID-Profile: Ludoviko Zirimenya, Gyaviira Nkurunungi
Förderung
- Science for Africa Foundation
- National Institute for Health and Care Research
- LSHTM ITD Faculty Equity
- MRC/UVRI & LSHTM Uganda Research Unit
- Medical Research Council
Zitieren
APA
Zirimenya, L., Nayebare, D., Baine, C., Nassuuna, J., Namutebi, M., Zziwa, C., Nsubuga, D., Kiwudhu, F., Akello, F., Tumusiime, J., Oduru, G., Kabami, G., Akurut, H., Nakyesige, R., Natukunda, A., Wajja, A., Lubyayi, L., Kimuda, S., Nkurunungi, G., …, & Elliott, A. M. (2026). Life Course Malaria Exposure and SARS ‐ CoV ‐2 Seroepidemiology in Ugandan Adolescents: A Longitudinal Study Nested in a Birth Cohort. Tropical Medicine & International Health, 31(8), 1012-1027. https://doi.org/10.1111/tmi.70148
Vancouver
Zirimenya L, Nayebare D, Baine C, Nassuuna J, Namutebi M, Zziwa C, et al. Life Course Malaria Exposure and SARS ‐ CoV ‐2 Seroepidemiology in Ugandan Adolescents: A Longitudinal Study Nested in a Birth Cohort. Tropical Medicine & International Health. 2026;31(8):1012-1027. doi:10.1111/tmi.70148
BibTeX
@article{Zirimenya2026,
author = {Zirimenya, Ludoviko and Nayebare, Doreen and Baine, Claire and Nassuuna, Jacent and Namutebi, Milly and Zziwa, Christopher and Nsubuga, Denis and Kiwudhu, Fred and Akello, Florence and Tumusiime, Josephine and Oduru, Gloria and Kabami, Grace and Akurut, Hellen and Nakyesige, Rachel and Natukunda, Agnes and Wajja, Anne and Lubyayi, Lawrence and Kimuda, Simon and Nkurunungi, Gyaviira and Serwanga, Jennifer and Doores, Katie J and Webb, Emily L and Elliott, Alison M},
title = {Life Course Malaria Exposure and SARS ‐ CoV ‐2 Seroepidemiology in Ugandan Adolescents: A Longitudinal Study Nested in a Birth Cohort},
journal = {Tropical Medicine & International Health},
year = {2026},
volume = {31},
number = {8},
pages = {1012--1027},
doi = {10.1111/tmi.70148}
}
EUVIMED